ABSTRACT
OBJECTIVE@#To observe the effect of anti-osteoporosis drugs on the curative effect of femoral head replacement in the elderly patients with proximal humerus fracture.@*METHODS@#From November 2012 to June 2016, 38 patients with proximal humeral fractures received humeral head replacement were divided into the treatment group and the control group according to whether the anti-osteoporosis drugs were used after the operation. The treatment group included 19 cases, of which 11 cases were three part fractures, 18 cases were four part fractures, and bone density was(0.58±0.14) g/cm²; the control group involved 19 cases, of which 10 cases were the three part fractures, 9 cases were four part fractures, and bone density was(0.58±0.11) g/cm². Periprosthetic bone mineral density(BMD) was measured at 4, 8, 12, 24 and 48 weeks after operation, and visual analogue scale(VAS) was used to evaluate the pain and Neer score was used to evaluate the function of the shoulder joint.@*RESULTS@#The incisions of all patients were healed with grade A and no complications occurred. Thirty-five patients were followed up for 1 year. The bone density around the prosthesis of treatment group was higher than that of control group, the difference was statistically significant(0.05). The total score and functional score of Neer in the treatment group were better than those in the control group, the difference was statistically significant(0.05). According to the Neer score, the results of treatment group was excellent in 10 cases, good in 5 cases, fair in 3 cases;in the control group, 3 cases were excellent, 9 cases were good, and 5 cases were fair;the difference between the two groups was statistically significant(<0.05).@*CONCLUSIONS@#Artificial humeral head replacement combined with anti-osteoporosis drugs in the treatment of proximal humeral fractures in elderly patients can effectively improve the bone density around the prosthesis and restore shoulder function. The early clinical effect is satisfactory.
Subject(s)
Aged , Humans , Calcitonin , Therapeutic Uses , Fracture Fixation, Internal , Humeral Head , Postoperative Period , Shoulder Fractures , Shoulder Joint , Treatment OutcomeABSTRACT
Objective To observe the clinical effect of acupoint injection of salmon calcitonin in the treatment of senile osteoporosis. Methods From February 2016 to July 2017,136 elderly patients with osteoporosis admitted to Wenzhou Hospital of Traditional Chinese Medicine were included. The patients were randomly divided into two groups,with 68 cases in each group. The acupoint-injection group was given 50IU salmon calcitonin on day 1, day 2 100IU, one time per day, continuously used for 15 days for a course of treatment, and with an interval of 90 days,and repeat the course of treatment. The patients were given 0. 9% sodium chloride diluted to 2mL,inject 0. 5mL into bilateral Shenshu and Zusanli these two points. The intramuscular injection group was given the same dose of salmon calcitonin gluteus maximus injected intramuscularly. At the same time,both two groups were given calcium Erqi D tablets one tablet a day,alendronate once a week,each time 70mg fasting taken orally. The type Ⅰ collagen β-CTx,PINP,NBAP,femoral neck,femur trochanter,lumbar (L1 -L4) lumbar BMD and osteoporosis symptom score before and after treatment were compared. Results After treatment,the NBAP and BMD of the two groups were significantly higher than those before treatment (all P<0. 05),and the β-CTx,PINP and symptoms scores were lower than before treatment (P<0. 05). After treatment,NBAP in the acupoint injection group was (32. 36 ± 3. 03)μg/L, which was higher than (29. 66 ± 3. 20) μg/L in the intramuscular injection group(t =10. 477,P <0. 05). The β-CTx and PINP in the acupoint injection group were decreased to (0. 10 ± 0. 05)μg/L and (28. 78 ± 5. 23)μg/L, which were significantly lower than those in the intramuscular injection group[β-CTx(0. 20 ± 0. 05)μg/L,PINP (35.77 ±6. 49)μg/L(t =5. 983,2. 662,all P <0. 05)]. After treatment,the BMD of the femoral neck,femur trochanter and lumbar vertebra (L1 -L4) in the acupoint injection group were (0. 690 ± 0. 032)g/m2,(0. 620 ± 0. 010)g/m2and (0. 822 ± 0. 012)g/m2,respectively,which were higher than those in the intramuscular injection group[(0.652 ±0.012)g/m2,(0.572 ±0.022)g/m2and (0.801 ±0.011)g/m2(t=5.055,6.133,1.956,all P<0. 05)]. After treatment,the improvements of TCM syndromes such as weakness in the waist and knees,tinnitus and deafness,loss of appetite,release of teeth,relaxation of two feet,weak tongue,weak pulse in the acupoint injection group were better than those in the intramuscular injection group (all P<0. 05). Conclusion The acupoint injection of salmon calcitonin at Zusanli and Shenshu points is more effective than the intramuscular injection in the treatment of senile osteoporosis. It can significantly increase the serum NBAP,decrease the serum β-CTx,PINP,improve the BMD and improve the patients'clinical symptoms,which means acupoint injection is a safe and effective way to treat senile osteoporosis.
ABSTRACT
Objective To discuss the treatment effect and application value of salmon calcitonin nasal spray in the patients with postmenopausal osteoporosis.Methods 130 patients with postmenopausal osteoporosis were divided into observation group and control group by random number method,65 cases in each group.The control group was given calcium and alfacalcidol treatment,the observation group received in combination with salmon calcitonin nasal spray treatment.The clinical effect of the two groups was recorded.Results The total effective rate of the treat-ment group was 95.38%,which of the control group was 84.62%,the difference between the two groups was statisti-cally significant (χ2 =4.188,P<0.05 ).After treatment,the tuberosity bone mineral density,femoral neck BMD, L1 -4 lumbar spine bone mineral density of the observation group were (0.69 ±0.15)g/cm2,(0.77 ±0.21)g/cm2, (0.98 ±0.26)g/cm2,which of the control group were (0.52 ±0.08)g/cm2,(0.64 ±0.13)g/cm2,(0.81 ± 0.15)g/cm2,the differences between the two groups were statistically significant (t=8.062,4.243,4.566,all P<0.05).After treatment,the calcitonin,beta collagen fragment,osteocalcin of the observation group were (2.97 ± 0.86)ng/L,(0.11 ±0.01)ng/mL,(7.18 ±1.14)ng/mL,which of the control group were (2.41 ±0.43)ng/L, (0.35 ±0.08)ng/mL,(15.89 ±3.53)ng/mL,the differences between the two groups were statistically significant (t=4.695,24.000,18.930,all P<0.05).Conclusion Salmon calcitonin nasal spray in the treatment of patients with postmenopausal osteoporosis can reduce pain,inhibit osteoclast activity,promote bone formation,prevent bone loss and increase bone mass,it is safe and worthy of popularizing in clinical application.
ABSTRACT
Objective To invcstigate the clinical effect of Bushenxuanfei decoction combined with salmon calcitonin on osteoporosis in COPD patients.Methods 60 COPD patients with osteoporosis were randomly divided into two groups:30 patients as controls were treated with calcium carbonate and vitamin D3 tablets and salmon calcitonin and another 30 patients in the treatment group with salmon calcitonim combined with Bushenxuanfei decoction.The two groups were compared in terms of pain,BMD and calcium concentration.Results The treatment group was significantly better than the control one in terms of indexes of pain BMD and calcium concentration (P<0.05).Conclusion Bushenxuanfei decoction combined with salmon calcitonin is of significant effect in the treatment of osteoporosis in COPD patients.
ABSTRACT
Objective To evaluation of curative effect of Yiqi-Wenshen decoction combined with salmon calcitonin subcutaneous injection for the patients with postoperative bone atrophy after calcaneal fracture.Methods According to the inclusion criteria, 120 patients with calcaneal fracture were randomly divided into 2 groups, 60 in each group. The control group received the subcutaneous injection of salmon calcitonin, and the combined group received the control group treatment plus Yiqi-Wenshen decoction. Both groups were treated for 6 weeks. The X-ray was used to detecte the local bone density of limbs, and the foot function scores of ankle function and the changes of clinical symptoms and signs before and after treatment were observed.Results After treatment, joint pain (2.8 ± 1.1vs. 3.6 ± 1.1,t=4.129), tenderness (1.0 ± 0.5vs. 1.4 ± 0.7,t=3.297), the color change of (1.5 ± 0.8vs. 2.0 ± 0.6,t=3.117) score in the combined group were significantly lower than those in the control group (P<0.05). The degree of swelling (112.5 ± 11.8 cm3vs. 122.5 ± 13.6 cm3,t=3.816) in the combined group was significantly lower than that in control group (P<0.05). The bone mineral density (0.762 ± 0.020 g/cm2vs. 0.722 ± 0.023 g/cm2,t=3.803,P<0.05) in the combined group was significantly higher than that in the control group. The effect rate of the combined group was 90% (54/60), and the control group was 70%. There was significant difference between 2 groups (χ2=7.500,P=0.006). The effect rate of ankle joint function of the combined group was 83.3% (50/60), and the control group was 70% (42/60). There was significant difference between 2 groups (χ2=4.444,P=0.035).Conclusions The Yiqi-Wenshen decoction combined with subcutaneous injection of salmon calcitonin could relieve the pain, swelling and other symptoms of the patients with bone atrophy after calcaneal fractures, and could benefit the recovery of ankle joint function.
ABSTRACT
Objective To investigate the clinical effect of salmon calcitonin in the treatment of senile osteoporosis , and to observe the effect of salmon calcitonin on bone mineral density ( BMD ) and pain.Methods 180 cases of patients diagnosed as osteoporosis from September 2015 to September 2016 in our hospital were retrospectively analyzed, the patients were divided into control group and treatment group according to the random number table method.The clinical efficacy and side effects of the two groups were evaluated.The bone mineral density (BMD) of the lumbar vertebrae, femur and radius were measured by dual energy X-ray absorptiometry.The VAS was used to evaluate the two groups before and after the treatment.( ODI) were used to evaluate the functional status of the patients before and after treatment.The self-made questionnaire was used to evaluate the quality of life of the patients before and after treatment.Results The total effective rate of treatment group was 94.44%, significantly higher than the control group 75.56%(P<0.05).After treatment, the treatment group of lumbar spine bone mineral density, bone mineral density and radial bone mineral density was significantly higher than the control group (P<0.05).After treatment, spontaneous low back pain, flexion extension pain, turn over pain and weight pain were significantly lower in the treatment group than in the control group (P<0.05).The ODI index of the treatment group was significantly lower than that of the control group (P<0.05).After treatment, the quality of life scores in the two groups were significantly higher than those before treatment, and the treatment group was higher than the control group(P<0.05).No significant adverse reactions occurred in two groups during the treatment.Conclusion Salmon calcitonin treatment of osteoporosis in elderly patients with a significant effect, help to improve bone mineral density, reduce pain and improve its dysfunction, and has high security.
ABSTRACT
<p><b>OBJECTIVE</b>To verify the clinical efficacy on postmenopausal osteoporosis treated with acupoint injection of salmon calcitonin.</p><p><b>METHODS</b>Ninety patients of postmenopausal osteoporosis were randomized into three groups, 30 cases in each one. In the acupoint injection group, Shenshu (BL 23) and Zusanli (ST 36) were selected bilaterally. The injection 4 mL was prepared with salmon calcitonin 100 U (1 mL) and 0.9% sodium chloride injection. Each acupoint was stimulated with the injection, 1 mL. In the blank group, 0.9% sodium chloride injection was applied to bilateral Shenshu (BL 23) and Zusanli (ST 36), 1 mL at each acupoint. In the intramuscular injection group, salmon calcitonin 100 U was injected at gluteus maximus. The treatment was given once every two days in the patients of the three groups and lasted for 2 months. The levels of bone mineral density (BMD), bone alkaline phosphatase (NBAP), C-terminal telopeptides of typeⅠcollagen (CTX), urine calcium/creatinine (Ca/Cr) and the symptom score of osteoporosis were detected in the patients of the three groups before and after treatment.</p><p><b>RESULTS</b>In the patients of the three groups, NBAP and BMD in lumbar vertebra after treatment were higher than those before treatment (all<0.05); CTX, Ca/Cr and symptom score were lower than those before treatment (all<0.05). After treatment, NBAP was (32.7±2.5) μg/L in the acupoint injection group, higher than those in the blank group and the intramuscular injection group (both<0.05). In the acupoint injection group, CTX was reduced to (239.7±63.6) μmmol/L and Ca/Cr was reduced to 0.525±0.274, apparently lower than those in the blank group and intramuscular injection group (both<0.05). After treatment, in the acupoint injection group, BMD of lumbar vertebra was (0.731±0.062) g/m, higher than the level of the rest two groups (both<0.05). After treatment, the symptom score was 5.2±0.6 in the acupoint injection group, lower than those in the blank group and intramuscular injection group (both<0.05).</p><p><b>CONCLUSIONS</b>Salmon calcitonin injec-tion at Zusanli (ST 36) and Shenshu (BL 23) achieves significant efficacy on postmenopausal osteoporosis, stimulating osteoblast activity and inhibiting bone absorption of osteoclast.</p>
ABSTRACT
Objective To observe the effect of proximal femoral nail anti-rotation(PFNA)combined with salmon calcitonin for the treatment of unstable intertrochanteric fractures in the elderly.Methods A total of 90 elderly patients with unstable intertrochanteric frac-tures were randomly divided into group A,group B and group C(30 cases in each group).Patients in group A received open reduction with DHS,patients in group B got closed reduction with PFNA,and patients in group C received operation as group B but combined with salmon calcitonin after the operation.The intraoperative and postoperative stuation of three groups were compared.Results The intraoperative and postoperative stuation of group B was better than those of group A,the time of weight-bearing exercise and fracture healing in group C was shorter than those of group B(t =4.42;t =5.0,P <0.05).The group B had a less complication than group A(χ2 =7.03,P <0.05).Con-clusion The PFNA has a good restoration effect with shorter operative time,less bleeding and lower complication rate.And combined with the salmon calcitonin,which can shorten the time of recovery.
ABSTRACT
OBJECTIVE:To investigate clinical efficacy and safety of conjugeted estrogen tablets combined with Salmon calci-tonin acetate injection and Alendronate sodium tablets in the treatment of osteoporosis in postmenopausal. METHODS:148 post-menopausal women with osteoporosis were randomly divided into observation group(78 cases)and control group(70 cases). Con-trol group was given Salmon calcitonin acetate injection hypodermically or intramuscularly,100 IU each time,once a day in first week,every two days in second week,every three days in third week,21 times of consecutive injection as a treatment course;Alendronate sodium tablet,70 mg each time,once a week,3 months as a treatment course. Based on control group,observation group was additionally given conjugeted estrogen tablets,0.625 mg each time,qd,for consecutive 3 weeks,drug withdrawal for one week,and then continued to taking drug,for 3 months in total. Clinical efficacy of 2 groups were observed as well as BGP, bone metabolism index as human collagen type Ⅰ N-terminal peptide (NTX) and ALP,bone density and ADR before and after treatment. RESULTS:After treatment,total effective rate of observation group was 94.87%,which was significantly higher than 78.57% in control group,with statistical significance(P0.05);various ADR disappeared after drug withdrawal. CONCLUSIONS:Conjugeted estrogen tablets combined with Salmon calcitonin acetate injection and Alendronate sodium tablets can effectively relieve bone pain,regulate bone metabolism,increase bone density and induce slight ADR in postmenopausal with osteoporosis.
ABSTRACT
@#Objective To explore the effect of salmon calcitonin on osteoporosis induced by spinal cord injury. Methods 100 patients with osteoporosis induced by spinal cord injury from September 2011 to September 2014 in our department were included. They were randomly divided into control group (n=50) and observation group (n=50). The control group received vitamin D3 only, while the observation group received vitamin D3 combined with salmon calcitonin on the basis of rehabilitation physiotherapy, for 6 months. Visual Analogue Scale (VAS) of pain was evaluated in different periods. The bone mineral density (BMD) of lumbar spine and femoral neck, the parathyroid hormone (PTH), bone gla protein (BGP) and 1,25- dihydroxy vitamin D3 (1,25-(OH)2D3) were tested and recorded. Results The VAS score was lower in the observation group than in the control group 1, 2, 3 and 6 months after treatment (P<0.001). The BMD of lumbar spine and femoral neck was significantly higher, the PTH and BGP were significantly lower and the 1,25-(OH)2D3 was significantly higher in the observation group than in the control group after treatment (P<0.001). Conclusion Combination of salmon calcitonin can effectively reduce the bone pain and improve the BMD in patients with osteoporosis induced by spinal cord injury.
ABSTRACT
Objective To explore the effect of salmon calcitonin on osteoporosis induced by spinal cord injury. Methods 100 patients with osteoporosis induced by spinal cord injury from September 2011 to September 2014 in our department were included. They were ran-domly divided into control group (n=50) and observation group (n=50). The control group received vitamin D3 only, while the observation group received vitamin D3 combined with salmon calcitonin on the basis of rehabilitation physiotherapy, for 6 months. Visual Analogue Scale (VAS) of pain was evaluated in different periods. The bone mineral density (BMD) of lumbar spine and femoral neck, the parathyroid hormone (PTH), bone gla protein (BGP) and 1,25-dihydroxy vitamin D3 (1,25-(OH)2D3) were tested and recorded. Results The VAS score was lower in the observation group than in the control group 1, 2, 3 and 6 months after treatment (P<0.001). The BMD of lumbar spine and femoral neck was significantly higher, the PTH and BGP were significantly lower and the 1,25-(OH)2D3 was significantly higher in the obser-vation group than in the control group after treatment (P<0.001). Conclusion Combination of salmon calcitonin can effectively reduce the bone pain and improve the BMD in patients with osteoporosis induced by spinal cord injury.
ABSTRACT
OBJECTIVE: To establish an LC-MS method for identification of the primary degradation impurities in domestic calcitonin salmon injections. METHODS: For the RPLC analysis., the separation was performed on Waters XTerra RP C18 column (3.0 mm × 50 mm, 3.5 μm) with linear gradient elution using 0.05% aqueous trifluoroacetic acid (A) and acetonitrile (B); the flow rate was 0.5 mL · min-1; the column temperature was 40℃; the detection wavelength was set at 220 nm. For the SEC analysis, the separation was performed on TSK GEL 2000SWxl column (7.8 mm × 300 mm, 5 μm) with mobile phase consisting of TFA-water-acetonitrile(0.05:80:20); the flow rate was 0.7 mL · min-1; the column temperature was room temperature; the detection wavelength was set at 220 nm; the main impurities were collected and identified by positive mode. RESULTS: The structures of three impurities were elucidated by RPLC-MS and SEC-MS. CONCLUSION: The results of this study can be applied in impurity profile analysis, specification research, and quality control of calcitonin salmon injections.
ABSTRACT
This study was conducted to determine if nasal salmon calcitonin has additional beneficial effects on clinical symptoms, serum NO, IL-1beta, matrix metalloproteinase 3, urinary C-terminal telopeptide type II collagen (CTX-II) levels and MRI findings in knee osteoarthritis (OA) when used concomitantly with exercise therapy. Fifty female patients with knee OA were randomized into two groups. The first group (n = 30) received 200 IU/day nasal salmon calcitonin and a home exercise program; the second group (n = 20) received a home exercise program for 6 months. Compared with baseline,while significant improvements were observed in visual analogue scale (VAS), WOMAC pain, physical function scores, 20-m walking time (P < 0.001) and WOMAC stiffness score (P = 0.041) in the first group, walking and resting VAS, and WOMAC physical function scores were improved (P = 0.029) in the second group after treatment. Significantly increased levels of serum NO and urinary CTX-II (P < 0.001) and significant improvements in the area of medial femoral condyle (P < 0.05) were noted only in the first group. There were significant differences in VAS activation values (P = 0.032) and NO levels (P < 0.001) in the favor of the first group. In conclusion, nasal salmon calcitonin may have possible chondroprotective effects besides its known effects on symptoms in patients with knee OA.
Subject(s)
Aged , Female , Humans , Middle Aged , Bone Density Conservation Agents/therapeutic use , Calcitonin/therapeutic use , Collagen Type II/urine , Exercise Therapy , Interleukin-1beta/blood , Magnetic Resonance Imaging , Matrix Metalloproteinase 3/blood , Nitric Oxide/blood , Osteoarthritis, Knee/drug therapy , Peptide Fragments/urine , Respiratory Therapy , Severity of Illness Index , Treatment Outcome , WalkingABSTRACT
This study was conducted to determine if nasal salmon calcitonin has additional beneficial effects on clinical symptoms, serum NO, IL-1beta, matrix metalloproteinase 3, urinary C-terminal telopeptide type II collagen (CTX-II) levels and MRI findings in knee osteoarthritis (OA) when used concomitantly with exercise therapy. Fifty female patients with knee OA were randomized into two groups. The first group (n = 30) received 200 IU/day nasal salmon calcitonin and a home exercise program; the second group (n = 20) received a home exercise program for 6 months. Compared with baseline,while significant improvements were observed in visual analogue scale (VAS), WOMAC pain, physical function scores, 20-m walking time (P < 0.001) and WOMAC stiffness score (P = 0.041) in the first group, walking and resting VAS, and WOMAC physical function scores were improved (P = 0.029) in the second group after treatment. Significantly increased levels of serum NO and urinary CTX-II (P < 0.001) and significant improvements in the area of medial femoral condyle (P < 0.05) were noted only in the first group. There were significant differences in VAS activation values (P = 0.032) and NO levels (P < 0.001) in the favor of the first group. In conclusion, nasal salmon calcitonin may have possible chondroprotective effects besides its known effects on symptoms in patients with knee OA.
Subject(s)
Aged , Female , Humans , Middle Aged , Bone Density Conservation Agents/therapeutic use , Calcitonin/therapeutic use , Collagen Type II/urine , Exercise Therapy , Interleukin-1beta/blood , Magnetic Resonance Imaging , Matrix Metalloproteinase 3/blood , Nitric Oxide/blood , Osteoarthritis, Knee/drug therapy , Peptide Fragments/urine , Respiratory Therapy , Severity of Illness Index , Treatment Outcome , WalkingABSTRACT
In order to make a histomorphometric evaluation of the dental alveolus wound healing in chronic presence of salmon-calcitonin (16UI/Kg) in the diabetic condition, sixty albino rats were utilized. These animals were divided into three groups: control(C), diabetic (D) and calcitonin-treated diabetic (Dca). The D and Dca groups were given a single 45mg/Kg intraperitonial injection of streptozotocin-STZ. After two weeks, all animals were submitted a tooth extraction of the upper right incisor and five animals from each group were sacrificed at 15, 30 e 45 post-operative days. The pieces were fixed, descalcified and embedded in paraffin. The blocks thus obtained were cut at 6 micrometers thick and sections were stained with hematoxylin and eosin for morphological study. According to the results obtained it was verified that the calcitonin-treated animals altered of wound healing after dental extraction, attenuating the impairment of the bone repair dynamic commonly observed in the diabetic status.
A fim de fazer uma avaliação histomorfométrica da cicatrização em feridas crônicas do alvéolo dental na presença de calcitonina de salmão (16UI/Kg) em 60 ratos albinos diabéticos. Estes animais foram divididos em três grupos: controle (C), diabético (D) e diabéticos tratados com calcitonina (Dca). Os grupos D e Dca receberam uma injeção única 45mg/Kg intraperitonial de estreptozotocina-STZ. Depois de duas semanas, todos os animais foram submetidos a exodontia do dente incisivo superior direito e cinco animais de cada grupo foram sacrificados aos 15, 30 e 45 dias pós-operatórios. As peças foram fixadas, descalcificadas e embebidas em parafina. Dessa forma os blocos obtidos foram cortados com 6 micrômetros de espessura e foram corados com hematoxilina e eosina para estudo morfológico. De acordo com os resultados obtidos, verificou-se que os animais tratados com calcitonina tiveram a cicatrização da ferida após a exodontia dentária alterada, o que atenuou o comprometimento da reparação óssea, geralmente observada no estado diabético.
Subject(s)
Animals , Rats , Calcitonin , Diabetes Mellitus , StreptozocinABSTRACT
Objective To study the changes of bone mineral density(BMD)and bone turnover in postmenopausal osteoporotic patients treated with salmon calcitonin nasal spray. Methods Sixty-seven postmenopausal osteoporotic patients were enrolled in our trial. All of them received calcium and vitamin D; 37patients were treated with salmon calcitonin nasal spray for 12 months and the other 30 patients received calcium and vitamin D only. Dual-energy X-ray absorptiometry(DEXA)and measurements of a series of bone turnover indices were performed before and after medication for 6 and 12 months. Results After treatment with salmon calcitonin nasal spray for6 months, BMD in lumbar spine 2-4 increased but no change occurred in femoral neck. However, after treatment for 12 months, BMD in both lumbar spine 2-4 and femoral neck increased. In the control group, BMD in lumbar spine 2-4 decreased after treatment for 6 and 12 months, but BMD in femoral neck decreased only after 12months. Comparing with the control group, after treatment with salmon calcitonin nasal spray, BMD in lumbar spine 2-4 and femoral neck were increased obviously. The level of TRACP-5b and NTX/Cr decreased after treatment with salmon calcitonin nasal spray for6 months and 12 months, while BALP increased only after treatment for 12 months. In the control group, BALP decreased after treatment for 12 months. The level of 25-(OH)vitamin D increased after treatment for 6 months and 12 months in both groups. Conclusions Long-term treatment with salmon calcitonin nasal spray prevents bone loss and may increase bone mass.
ABSTRACT
Objective To study effects of salmon calcitonin and Heng Gu bone healing reagent on vertebral osteoporotic fracture(OPF).Methods From Nov.2007 to Dec.2009,82 cases of vertebral OPF were treated.These cases were randomly divided into treatment group and control group.The treatment group(42 cascs)were treated with salmon calcitonin and Heng Gu bone healing reagent.The control group(40 cases)received salmon calcitonin only.Pain relief of the 2 groups wag compared.Results Before treatment,the 82 patients were scored 6-9 points by visual analogue scales(VAS)and pain scores of the 2 groups were similar (P>0.05).3 days,5 days,8 days and 15 days after treatment,VAS scores of the 2 groups were significantly different(P<0.01).Compared to the control group,the treatment group had pain relief in shorter time and their bone mineral density Was better showed by the 3-month-later review.Conclusion The combination therapy of salmon calcitonin and Heng Gu bone healing reagent in treating vertebral OPF has better effect of pain relief and bone formation,which is a safe and effective method.
ABSTRACT
Objective To study the effect of long-term salmon calcitonin on bone mineral density (BMD), bone metabolism biochemical indicators and subjective score of bone pain in maintenance hemedialysis (MHD) patients with osteopenia. Methods Thirty-four MHD patients diagnosed as osteopenia by dual-energy X-ray absorptiometry (DXEA) were enrolled in this study. All the patients were treated with hypodermic injection of salmon calcitonin (50 U, thrice a week) for 12 months. The detecting parameters were as follows: BMD with DEXA in lumbar spine (L1-L4), femoral neck, troch, inter, and Ward's triangle before and after the study;serum bone metabolism biochemical indicators before and 6 and 12 months after the study;subjective scores of bone pain before and 1, 6, and 12 months after the study. Results Thirty-two patients were followed-up successfully. As compared to BMD parameters before study, the total T-score (-1.98± 2.20 vs 1.26±1.88, P=0.009) and total Z-score (-0.90±2.15 vs 0.08±2.05, P=0.002) of lumbar spine, the total T-score (-1.72±1.53 vs 1.06±1.58, P=0.016) and totle Z-score (-0.66±0.80 vs 0.08±1.08, P=0.029) of hip, the T-score of L3 (-2.02±2.51 vs 1.24±2.02, P=0.033), the Z-score of L2 (-0.44±1.82 vs 0.06±1.63, P=0.016), the Z-score of femoral troch (-0.65±1.11 vs 0.48±1.12, P=0.034) and the Z-score of inter (-0.58±0.94 vs 0.02±1.12, P=0.006) were increased significantly after study. But there were no significant differences in other examined regions and serum biochemical parameters. The subjective scores of bone pain were decreased rapidly for 41.7% after 1 month (P<0.01) and 76.6% after 6 months (P<0.01). The subjective score of bone pain after 12 months was similar to 6 months. The side effects of salmon calcitonin included nausea and vomitting in 5 cases (14.71%, 5/34), dizziness, blushing and flustered in 1 case respectively (3.13%,1/32). Conclusions Long-term hypodermic injection of salmon calcitonin can improve BMD and bone pain for MHD patients with osteopenia but has no significant effect on serum bone metabolism biochemical indicators. Salmon calcitonin is safe for MHD patients with seldom side effects, such as nausea and vomitting.
ABSTRACT
Objective To investigate the effect of Bushenzhuanggutang combined with salmon calcitonin see calcimar in the treatment of renal osteodystrophy,and explore the mechanism of treatment.Methods 48 patients with renal osteodystrophy were divided into two groups:combined treatment group and control group.The patients were treated with Bushenzhuanggutang and salmon calcitonin see calcimar in combined treatment group.The patients were treated with salmon calcitonin see calcimar in the other group.Then the levels of serum calcium、phosphorus,PTH and BUN、Scr were detected before and after the treatment.Results The level of serum calcium increased significantly in two groups,while the level of serum phosphorus and PTH decreased(P
ABSTRACT
OBJECTIVE:To evaluate the cost-effectiveness of2different administration regimens for treatment for pains in waist and back caused by osteoporosis.METHODS:123patients were randomly divided into2groups,Group A underwent salmon calcitonin nasal spray,Group B received salmon calcitonin intramuscular injection,2different regimens of administration were evaluated using pharmacoeconomic cost-effectiveness analysis.RESULTS:The total costs in Group A and B were1596yuan and2634.66yuan,respectively(P0.05);And the ratios of cost-effectiveness16.8and27.7,respectively.CONCLUSION:Regimen A is preferred to regimen B.